Educational guide for research and informational purposes only. Not medical advice.
Most people approach peptides the way they approach supplements: one thing at a time, no context, no stack logic. That's why most people get mediocre results.
The compounds that produce serious fat loss outcomes — the kind that actually shows up in the mirror — are almost always running in combination. This is a breakdown of the specific stacks, why each combination works mechanistically, and how to think about layering them based on your goal.
Why Stacking Works: The Multi-Pathway Logic
Fat loss is a multi-system problem. No single peptide addresses all of it. That's the argument for intelligent stacking:
- Appetite and caloric intake — controlled by GLP-1, GIP, glucagon signaling
- Fat mobilization (lipolysis) — driven by GH, catecholamines, glucagon, hormone-sensitive lipase activation
- Fat oxidation (actually burning it) — mitochondrial function, beta-oxidation enzymes, respiratory chain efficiency
- Lean mass preservation — GH axis, IGF-1, testosterone, mTOR signaling during deficit
- Metabolic rate — thyroid, GH, glucagon-mediated thermogenesis, mitochondrial uncoupling
Stack 1: The GLP-1 + GH Axis Stack (Most Popular, Most Evidence)
Goal: Maximum fat loss while preserving lean muscle
This is the stack that separates people who lose weight from people who change their body composition.
The combination:
- Semaglutide + B12 or Tirzepatide + B12 — appetite suppression + caloric deficit creation
- CJC-1295 / Ipamorelin 10mg/10mg — GH pulse stimulation for lean mass retention and fat mobilization
Why it works:
GLP-1 therapy creates the caloric deficit. CJC-1295 + Ipamorelin stimulates growth hormone pulses that shift the metabolism toward fat oxidation and away from muscle catabolism. This is the physiological answer to the lean mass problem that GLP-1 monotherapy creates.
GH directly activates hormone-sensitive lipase in adipose tissue — mobilizing stored fat for fuel. During a GLP-1-induced caloric deficit, this means fat is being mobilized and the body has a reason to keep muscle tissue.
Protocol notes:
- GLP-1: titrate per standard protocol (start low, advance every 4 weeks)
- CJC-1295 / Ipamorelin: typically 100–200mcg/peptide, SC, before bed or post-workout
- Run for minimum 12 weeks to see meaningful body composition shift
Stack 2: The Triple Threat (Advanced — Maximum Fat Loss)
Goal: Aggressive fat loss for those who've already run GLP-1 monotherapy
The combination:
- Retatrutide 10mg — GLP-1 + GIP + Glucagon triple agonism; 24% mean weight loss in Phase 2 trials
- Tesamorelin 10mg — FDA-studied GHRH analog; clinical evidence for visceral fat reduction
- MOTS-C 10mg — mitochondrial function + insulin sensitivity via AMPK activation
Why it works:
Retatrutide brings the most aggressive receptor profile currently in research — the glucagon component specifically increases resting metabolic rate and hepatic fat oxidation in ways neither semaglutide nor tirzepatide can match.
Tesamorelin was studied in FDA-reviewed trials specifically for visceral adipose tissue reduction — it's the GHRH analog with the most direct clinical evidence for abdominal fat loss. It complements the metabolic effects of triple agonism without redundancy.
MOTS-C improves mitochondrial efficiency, which means the fat being mobilized by retatrutide and tesamorelin is actually burned more effectively at the cellular level — reducing the fraction that's re-esterified and stored.
Stack 3: The Metabolic Optimizer Stack
Goal: Fat loss through metabolic upregulation without GLP-1 appetite suppression
For those who can't use or don't want GLP-1 therapy but want a research-grade fat loss protocol that doesn't rely on appetite suppression.
The combination:
- Tesamorelin 5mg — visceral fat + GH release
- MOTS-C 10mg — mitochondrial efficiency + AMPK activation
- SLU-PP-332 5mg — ERRα agonist / exercise mimetic; upregulates fat oxidation gene expression
- NAD+ 500mg — cellular energy production; sirtuin activation; mitochondrial cofactor
Why it works:
This stack works from the bottom up — rather than suppressing appetite, it increases the body's capacity to burn fuel. MOTS-C activates AMPK, switching cells into fat-burning mode. SLU-PP-332 activates estrogen-related receptors that mimic aerobic exercise adaptations — increasing mitochondrial density and fat oxidation enzyme expression. NAD+ fuels the entire process at the mitochondrial cofactor level. Tesamorelin drives GH-mediated lipolysis on top of all of it.
This is the stack for people who train hard and want their metabolism running at its ceiling.
Stack 4: The Women's Body Recomposition Stack
Goal: Fat loss + lean retention + skin quality for female physiology
Women face a specific challenge during significant weight loss: skin elasticity and connective tissue quality become major determinants of the visual outcome. This stack pairs aggressive fat loss with tissue-quality support.
The combination:
- Tirzepatide + B12 — dual GLP-1/GIP agonist; best-in-class appetite regulation and fat loss
- GHK-Cu 50mg — collagen synthesis upregulation, skin tightening, tissue integrity
- GLOW Blend (BPC-157 / GHK-Cu / TB-500) — recovery, skin quality, and connective tissue remodeling
Why it works:
GHK-Cu is a copper tripeptide with robust evidence for collagen synthesis upregulation, skin tightening, and tissue repair — modulating expression of over 4,000 genes including collagen I, III, and IV, elastin, and inhibitors of matrix metalloproteinases. The GLOW Blend combines it with BPC-157's systemic healing properties and TB-500's tissue remodeling effects.
The result: you're losing fat and supporting the structural tissue underneath — which determines whether the end result looks like body recomposition or just deflation.
Stack 5: The Recovery-Optimized Fat Loss Stack
Goal: Fat loss for athletes who can't afford to lose performance or recovery capacity
Athletes cutting weight face a specific problem: caloric restriction degrades recovery, increases injury risk, and tanks performance. This stack addresses all three simultaneously.
The combination:
- Semaglutide + B12 (low dose) — mild appetite regulation without aggressive GI side effects
- Wolverine (BPC-157 / TB-500) 10mg/10mg — tissue recovery + injury prevention during high training load
- CJC-1295 / Ipamorelin — GH pulse for recovery and lean mass preservation
Why it works:
Low-dose GLP-1 creates a manageable deficit without aggressive appetite suppression that impairs athletic performance and fueling. Wolverine (BPC-157 + TB-500) directly addresses tissue recovery and reduces injury risk during increased training load. CJC-1295 / Ipamorelin keeps the GH axis active so muscle adaptation continues even in a deficit — and the nocturnal GH pulse supports sleep quality and overnight recovery.
The Non-Negotiable Variables
No stack works in isolation. The peptides create the biological environment — what you do in it determines the outcome.
Always included:
- Protein: 1.6–2.2g/kg/day minimum — preserves lean mass during deficit; provides amino acids for continued tissue repair
- Resistance training: 3–5 sessions/week — maintains the muscle protein synthesis signal; prevents lean mass loss during caloric restriction
- Sleep: 7–9 hours — GH is released primarily during slow-wave sleep; sleep deprivation suppresses GH, elevates cortisol, reduces insulin sensitivity, and accelerates fat storage
- Adequate hydration — particularly with GLP-1 therapy, which can cause fluid shifts and GI effects
Stack Comparison Summary
| Stack | Primary Mechanism | Best For |
|---|---|---|
| GLP-1 + GH Axis | Appetite suppression + lean preservation | Most people's best starting point |
| Triple Threat | Aggressive multi-receptor fat loss + metabolic rate | Advanced users, maximum fat loss |
| Metabolic Optimizer | Metabolic rate + mitochondrial function upregulation | Non-GLP-1 users, athletes, hard trainers |
| Women's Recomposition | Fat loss + tissue/skin quality support | Women prioritizing body composition quality |
| Recovery-Optimized | Deficit + performance and recovery preservation | Athletes, high training volume |
Starting Point
- Weight Loss Lab Panel — baseline biomarkers before starting any fat loss protocol
- Follow-Up Panel — confirm the protocol is working at 12–16 weeks
- Doctor's Consultation — recommended before initiating any GLP-1 or multi-compound protocol
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide — Phase 2 Trial. N Engl J Med. 2023.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007. (Tesamorelin)
- Lee C, et al. MOTS-c: A Mitochondrial-Derived Peptide Regulates Muscle and Fat Metabolism. Cell Metab. 2015.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018.
- Zhu W, et al. Pharmacological Activation of ERRα Mimics Endurance Exercise. J Am Chem Soc. 2023.
Educational Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any peptide protocol.
FitAF Performance — Educational content only.
